User Fees Called Positive

April 2010
Chain Drug Review;4/26/2010, Vol. 32 Issue 8, p194
Trade Publication
The article offers information on the Prescription Drug User Fee Act (PDUFA) and its significance to drug regulators and pharmaceutical industry in the U.S.


Related Articles

  • Manufacturers and FDA Gear Up for User-Fee Action. Wechsler, Jill // Pharmaceutical Technology;Sep2011, Vol. 35 Issue 9, p28 

    The article reports on the renewal of the prescription-drug user fees action (PDUFA) legislation for the pharmaceutical industry in the U.S. It explains that PDUFA reauthorization aims to improve drug approval process and spur biopharmaceutical research as well as drug development but the...

  • Briefly. Kondro, Wayne // CMAJ: Canadian Medical Association Journal;3/4/2009 Doctor's Health Matters, Vol. 180, p506 

    The article offers news briefs related to public health in the U.S. American pharmaceutical manufacturers are allowed to resume the medical journal articles distribution to physicians as part of health promotion. The National Institutes of Health won the congressional economic stimulus packages...

  • Dextropropoxyphene: withdrawal.  // WHO Drug Information;2010, Vol. 24 Issue 3, p215 

    The article discusses notices which several government agencies gave to health care professionals in New Zealand to remind them that the consent to distribute dextropropoxyphene containing medicines was revoked on August 1, 2010 and that it will no longer be legal to sell, distribute or...

  • Propoxyphene: recommendation against use.  // WHO Drug Information;2010, Vol. 24 Issue 4, p306 

    The article reports on a 2010 decision which the U.S. Food and Drug Administration made to recommend against the continued prescribing and use of the pain reliever propoxyphene because data showed that the drug can cause serious toxicity to the heart.

  • Plan to reduce drug errors eludes CSA.  // Medical Marketing & Media;Aug98, Vol. 33 Issue 8, p22 

    Reports on the failure of the United States Council on Scientific Affairs (CSA), to develop legislation to govern drug dispensing and prescribing errors. Recommendation of the CSA; Suggestion made by a US Food and Drug Administration representative at a US Reference Committee meeting.

  • Propoxyphene withdrawal not a crisis, pharmacists say. Traynor, Kate // American Journal of Health-System Pharmacy;1/1/2011, Vol. 68 Issue 1, p6 

    The article reports that the U.S. Food & Drug Administration (FDA) has urged health care providers to help patients who have been using propoxyphene to find alternatives to the pain medication that has been banned. Propoxyphene-containing products were withdrawn from the U.S. market in November...

  • New, recast Medicare prescription plans introduced. Hansen, Dave // AHA News;05/15/2000, Vol. 36 Issue 19, p3 

    Focuses on the medicare prescription drug plans introduced by the United States Senate Democrats. Purpose of the plans; Benefits of the plans; Senators who introduced the plans.

  • Congress Passes Medicare Bill.  // hfm (Healthcare Financial Management);Jan2004, Vol. 58 Issue 1, p11 

    Reports on the Medicare Prescription Drug bill passed by the U.S. Congress. Provision for a limited experiment in competition between private plans and traditional Medicare; Elimination of reductions in payments to teaching hospitals; Purpose of the bill.

  • BC's reference-based pricing stirs controversy. Kent, Heather // CMAJ: Canadian Medical Association Journal;4/18/2000, Vol. 162 Issue 8, p1190 

    Outlines objections to reference-based pricing that is government policy in British Columbia which requires doctors to prescribe less costly versions of medication. Repudiation that the reporting of $138 million dollars in savings actually costs taxpayers because it excludes program costs;...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics